日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

一项针对复发或难治性霍奇金淋巴瘤患者的 AFM13 联合帕博利珠单抗的 1b 期研究

Bartlett, Nancy L; Herrera, Alex F; Domingo-Domenech, Eva; Mehta, Amitkumar; Forero-Torres, Andres; Garcia-Sanz, Ramon; Armand, Philippe; Devata, Sumana; Izquierdo, Antonia Rodriguez; Lossos, Izidore S; Reeder, Craig; Sher, Taimur; Chen, Robert; Schwarz, Sylvia E; Alland, Leila; Strassz, Andras; Prier, Kim; Choe-Juliak, Cassandra; Ansell, Stephen M

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

口服塞利尼索选择性抑制核输出治疗复发或难治性多发性骨髓瘤

Vogl, Dan T; Dingli, David; Cornell, Robert Frank; Huff, Carol Ann; Jagannath, Sundar; Bhutani, Divaya; Zonder, Jeffrey; Baz, Rachid; Nooka, Ajay; Richter, Joshua; Cole, Craig; Vij, Ravi; Jakubowiak, Andrzej; Abonour, Rafat; Schiller, Gary; Parker, Terri L; Costa, Luciano J; Kaminetzky, David; Hoffman, James E; Yee, Andrew J; Chari, Ajai; Siegel, David; Fonseca, Rafael; Van Wier, Scott; Ahmann, Gregory; Lopez, Ilsel; Kauffman, Michael; Shacham, Sharon; Saint-Martin, Jean-Richard; Picklesimer, Carla D; Choe-Juliak, Cassandra; Stewart, A Keith